To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

In vivo retention of (18)… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

In vivo retention of (18)F-AV-1451 in corticobasal syndrome.

Journal article
Authors Ruben Smith
Michael Schöll
Håkan Widner
Danielle van Westen
Per Svenningsson
Douglas Hägerström
Tomas Ohlsson
Jonas Jögi
Christer Nilsson
Oskar Hansson
Published in Neurology
Volume 89
Issue 8
Pages 845-853
ISSN 1526-632X
Publication year 2017
Published at Institute of Neuroscience and Physiology
Pages 845-853
Language en
Subject categories Neurology, Radiology, Nuclear Medicine and Medical Imaging, Geriatrics


To study the usefulness of (18)F-AV-1451 PET in patients with corticobasal syndrome (CBS).We recruited 8 patients with CBS, 17 controls, 31 patients with Alzheimer disease (AD), and 11 patients with progressive supranuclear palsy (PSP) from the Swedish BioFINDER study. All patients underwent clinical assessment, (18)F-AV-1451 PET, MRI, and quantification of β-amyloid pathology. A subset of participants also underwent (18)F-FDG-PET.In the 8 patients with CBS, 6 had imaging findings compatible with the corticobasal degeneration pathology and 2 with typical AD pathology. In the 6 patients with CBS without typical AD pathology, there were substantial retentions of (18)F-AV-1451 in the motor cortex, corticospinal tract, and basal ganglia contralateral to the most affected body side. These patients could be clearly distinguished from patients with AD dementia or PSP using (18)F-AV-1451. However, cortical atrophy was more widespread than the cortical retention of (18)F-AV1451 in these CBS cases, and cortical AV-1451 uptake did not correlate with cortical thickness or glucose hypometabolism. These results are in sharp contrast to AD dementia, where (18)F-AV-1451 retention was more widespread than cortical atrophy, and correlated well with cortical thickness and hypometabolism.Patients with CBS without typical AD pathology exhibited AV-1451 retention in the motor cortex, corticospinal tract, and basal ganglia contralateral to the affected body side, clearly different from controls and patients with AD dementia or PSP. However, cortical atrophy measured with MRI and decreased (18)F-fluorodeoxyglucose uptake were more widespread than (18)F-AV-1451 uptake and probably represent earlier, yet less specific, markers of CBS.This study provides Class III evidence that (18)F-AV-1451 PET distinguishes between CBS and AD or PSP.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?